← Eichor
Study identifier: NCT06908668 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Condition: HER2-Negative Locally Advanced Breast Cancer  ·  Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

PhasePhase 2
Planned participants170
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Adebrelimab Combined with Chemotherapy with or without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

This description comes directly from the study's public registry record.

Talk to the study team

Fei Ma  ·  13910217780  ·  drmafei@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital, Chinese Academy of Medical SciencesBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06908668